Approved and selling, now Denali must sustain momentum
- AVLAYAH won FDA accelerated approval in March 2026 and generated $3.6 million in its first full commercial quarter.
- Management reported stronger than expected early demand, pricing AVLAYAH between $270,000 and $800,000 per year based on patient weight.
- Denali sold its rare pediatric disease priority review voucher in July for $195 million, adding to its cash reserves.
- The main question is whether AVLAYAH can hit its $10 million to $12 million third-quarter guidance and secure widespread insurer coverage.
- Takeda ended its partnership on DNL593 in April 2026, adding to a pattern of partner pullbacks across the pipeline.
The launch test is underway
Denali has cleared its biggest near-term hurdle. The FDA approved AVLAYAH for neurologic signs of Hunter syndrome in March 2026. The drug generated $3.6 million in its first full commercial quarter, moving the company officially into commercial biotech status.
The bull case is focused on launch execution. AVLAYAH early adoption has been stronger than expected, with management noting a large initial bolus of patients. Priced between $270,000 and $800,000 per year depending on weight, the drug could provide a revenue stream to fund Denali's other programs if it hits its $10 million to $12 million third-quarter guidance. The launch also provides real-world proof for Denali's Transport Vehicle platform, which carries large drugs across the blood-brain barrier.
The bear case centers on early launch risks and pipeline delays. A poor commercial rollout beyond the initial highly engaged patients would hurt confidence that Denali can shift from science to sales. AVLAYAH also holds accelerated approval, meaning the FDA can require proof of benefit in a confirmatory study. If the ongoing COMPASS study fails, the product could be pulled.
The next year has several swing factors. Investors will watch AVLAYAH sales, the BIIB122 LUMA readout in Parkinson's disease, Sanofi's eclitasertib data in ulcerative colitis, DNL593 data now expected in the first half of 2027, and completion of the DNL126 MPS IIIA study.
A drug delivery platform with a launched product
Denali's model starts with a hard problem. Many drugs cannot cross the blood-brain barrier, which is the body's natural shield around the brain. Its Transport Vehicle platform is designed to carry enzymes, proteins, antibodies, and oligonucleotides into the brain after intravenous dosing.
The company now earns revenue directly from AVLAYAH product sales, logging $3.6 million in the second quarter of 2026. It also earns collaboration revenue from partners like Sanofi and Biogen.
Funding also comes from alternative sources. Royalty Pharma agreed to provide up to $275 million in funding for a 9.25 percent royalty on future AVLAYAH sales, and Denali received $200 million of that in March 2026. In July 2026, the company sold its priority review voucher for $195 million, significantly strengthening its balance sheet.
The weak point is reliance on third parties. Denali needs a smooth rare disease launch, successful follow-up trials, and partner support for major programs. Takeda's exit from the DNL593 program shows that partners can leave even after a drug reaches human testing.
What Denali is selling and proving
AVLAYAH, tividenofusp alfa-eknm
AVLAYAH is Denali's first approved product. It treats neurologic manifestations in Hunter syndrome and generated $3.6 million in its first full quarter.
DNL126, ETV:SGSH
DNL126 is an enzyme therapy for Sanfilippo syndrome Type A, also called MPS IIIA. Denali is targeting a possible accelerated approval path in the second half of 2027.
BIIB122, DNL151
BIIB122 is a LRRK2 inhibitor for Parkinson's disease partnered with Biogen. Phase 2b LUMA data are expected in mid-2026.
Eclitasertib, SAR443122/DNL758
Eclitasertib is a peripheral RIPK1 inhibitor for ulcerative colitis partnered with Sanofi. A Phase 2 data readout is expected in the first half of 2026.
DNL593, PTV:PGRN
DNL593 is a progranulin therapy for frontotemporal dementia. Takeda terminated the collaboration in April 2026, and interim data is expected in the first half of 2027.
DNL952, ETV:GAA
DNL952 is an enzyme therapy for Pompe disease. A Phase 1 study is moving ahead.
DNL628 and DNL921
These are early-stage therapies for Alzheimer's disease. DNL628 is an ASO therapy and DNL921 is an anti-amyloid antibody, with data expected for both in 2027.
One reported business
Denali reports one operating and reportable segment: discovery and development of therapeutics to defeat degeneration. The company now recognizes product revenue from AVLAYAH alongside collaboration revenue.
What could break the thesis
Weak AVLAYAH launch
High impact · Medium oddsDenali is new to commercial sales. AVLAYAH must gain physician adoption, patient starts, and insurer coverage in a small rare disease market. A slow launch beyond the initial patient bolus would question the value of the first approval and the company's ability to sell its own drugs.
Confirmatory trial failure
High impact · Medium oddsAVLAYAH was approved through the accelerated pathway, which allows earlier approval based on evidence expected to predict benefit. Denali still needs confirmatory evidence. If the COMPASS study does not support benefit, the FDA could require label limits or withdrawal.
Partner exits keep spreading
High impact · Medium oddsTakeda ended the DNL593 collaboration in April 2026. That followed other recent partner exits, including Sanofi's CNS RIPK1 license termination and Takeda's ATV:TREM2 termination. More partner pullbacks would raise the cost for Denali and hurt trust in the pipeline.
Pipeline data disappoints
High impact · Medium oddsNeurodegenerative drug trials fail often. Denali has already seen DNL343 fail in ALS and several partnered programs stop. If BIIB122, DNL126, DNL593, or eclitasertib miss, the company could look too dependent on one rare disease product.
In one breath
What does Denali Therapeutics do?
Denali develops drugs for neurodegenerative and lysosomal storage diseases. Its main technology is the Transport Vehicle platform, which is designed to help large drugs cross into the brain.
Is Denali Therapeutics now a commercial company?
Yes. The FDA approved AVLAYAH in March 2026, and the company generated $3.6 million in sales during its first full quarter. However, most of its pipeline remains in clinical testing.
Why does AVLAYAH matter so much?
AVLAYAH is Denali's first approved drug and the first real commercial test of its platform. Strong sales support the bull case, while a weak launch would make investors question the platform's value.
What happened to the priority review voucher?
The FDA granted Denali a rare pediatric disease priority review voucher when AVLAYAH was approved. In July 2026, Denali successfully sold the voucher for $195 million.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Denali Therapeutics Inc. in Finn's Biotechnology industry ranking.
